Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Donepezil Hydrochloride in Patients With Dementia Associated With Cerebrovascular Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02660983
Recruitment Status : Completed
First Posted : January 21, 2016
Results First Posted : October 4, 2019
Last Update Posted : October 16, 2019
Sponsor:
Information provided by (Responsible Party):
Eisai Inc. ( Eisai Co., Ltd. )

Brief Summary:
The primary objectives are to confirm that donepezil hydrochloride has superior efficacy compared with placebo in improving cognitive function, as measured by Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-cog), and to demonstrate that donepezil hydrochloride has superior efficacy compared with placebo in improving global function, as measured by Clinician's Interview-Based Impression of Change-plus Caregiver Input (CIBIC-plus), in patients with dementia associated with cerebrovascular disease (VaD).

Condition or disease Intervention/treatment Phase
Dementia Associated With Cerebrovascular Disease Drug: Donepezil hydrochloride Drug: Donepezil matching placebo Phase 4

Detailed Description:
This is a multi-center, randomized, double-blind, placebo-controlled, parallel-group study with an open-label extension. The study consists of 3 phases; screening phase (1 to 4 weeks), double-blind phase (24 weeks), and Open-label extension phase (24 weeks). Participants, who have completed the double-blind phase and want to continue the study participation, can be enrolled in the 24-week open-label extension phase.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 302 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Donepezil Hydrochloride (E2020) in Patients With Dementia Associated With Cerebrovascular Disease
Actual Study Start Date : August 5, 2013
Actual Primary Completion Date : July 13, 2018
Actual Study Completion Date : December 21, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Dementia

Arm Intervention/treatment
Placebo Comparator: Double Blind Phase: Placebo
Participants will receive donepezil matching placebo, once daily in the evening during the double blind period.
Drug: Donepezil matching placebo
Experimental: Double Blind Phase: Donepezil
Participants will receive donepezil 5 milligram (mg), once daily in the evening during the titration phase and then the dose will be increased to 10 mg at Week 4 during the double blind period. During the maintenance period, dose reduction to 5 mg/day will be permitted only when 10 mg/day is intolerable due to adverse events.
Drug: Donepezil hydrochloride
Other Names:
  • E2020
  • Aricept

Experimental: Open-Label Extension Phase: Donepezil
All participants who will complete the double-blind phase and want to continue the study participation, can be enrolled in the 24-week open-label extension phase. In this phase, treatment will be initiated at 5 mg/day, and the dose will be maintained until Week 6 (Day 28-42). After assessing clinical response during the period by examination, the dose can be increased to 10 mg/day. Dose reduction (from 10 mg/day to 5 mg/day) will be permitted when the investigator judges it difficult to continue the 10 mg/day administration. It will be possible to increase the dose to 10 mg/day again.
Drug: Donepezil hydrochloride
Other Names:
  • E2020
  • Aricept




Primary Outcome Measures :
  1. Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog) Score (LOCF) at Week 24 [ Time Frame: Baseline and Week 24 ]
    The ADAS-Cog was a validated psychometric instrument that evaluates memory (word recall, word recognition), attention, reasoning (following commands), language (naming, comprehension), orientation, ideational praxis (placing letter in envelope) and constructional praxis (copying geometric designs). The ADAS-cog scores range from 0 to 70, with negative change from baseline indicating clinical improvement. LOCF=last observation carried forward.

  2. Clinicians Interview-based Impression of Change-plus Caregiver Input (CIBIC-plus) Score (LOCF) [ Time Frame: Week 24 ]
    The CIBIC-plus rates change in global functioning relative to baseline on a scale. The score ranges from 1 (Marked improvement) to 7 (Marked worsening). A score of "4" represents no change from baseline. LOCF=last observation carried forward.


Secondary Outcome Measures :
  1. Change From Baseline in Mini-mental State Examination (MMSE) Score (LOCF) at Week 24 [ Time Frame: Baseline and Week 24 ]
    MMSE is a well-known, gold standard test for measuring the cognitive state of dementia participants. It includes items evaluating orientation to time and place, recall of objects, attention, language, and conversational abilities. The total score ranges from 0 (most impaired) to 30 (no impairment). The lower score means severer cognitive deficit. A positive change score indicated improvement from baseline. LOCF=last observation carried forward.

  2. Change From Baseline in Executive Function Test (Korean Trail Making Test Elderly [K-TMT-e]) Score (LOCF) at Week 24 [ Time Frame: Baseline and Week 24 ]
    The trail making test (TMT) was an evaluation tool used to assess the cognitive function, especially for executive function. The K-TMT-e has two parts that are referred to as part A (component: serial numbers) and part B (component: serial numbers and days). The K-TMT-e was a timed test and the goal was to complete the tests accurately and as quickly as possible. Higher scores reveal greater impairment. K-TMT-e Score was measured as time taken by participants to complete goal. LOCF=last observation carried forward.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Patients who meet all of the following criteria will be eligible for inclusion in the study:

  1. Male or female, age greater than or equal to (>=) 40 years at the time of informed consent.
  2. Possible or probable dementia associated with cerebrovascular disease as defined by National Institute of Neurological Disorders and Stroke (NINDS) and the Association Internationale pour la Recherche et l'Enseignement en Neurosciences (AIREN) criteria (NINDS-AIREN Criteria) with dementia of greater than 3 months duration.
  3. Radiological evidence of cerebrovascular disease.
  4. Mini-Mental Status Examination (MMSE) score is ≥ 10 and ≤ 24.
  5. Clinical Dementia Rating (CDR) ≥ 1.
  6. Outpatients who are physically healthy, and ambulatory or ambulatory-aided (i.e., walker, cane or wheelchair).
  7. Written informed consent (IC) is obtained from the patient (if possible) and from the patient's legal guardian prior to being exposed to any study-related procedures. The caregiver must separately provide IC for his/her own participation in the study.
  8. Patients having caregivers who submit written consent to cooperate with this study, have regular contact with the patient (i.e., an average of ≥ 4 hours/day and ≥ 3 days/week), provide patients' information necessary for this study, ensure the regular administration of assigned donepezil, as well as all concomitant therapies, at the correct dose, and escort the patients on required visits to study institution.
  9. Comorbid medical conditions are clinically stable prior to Baseline, unless otherwise specified.

Exclusion Criteria

Patients who meet any of the following criteria will be excluded:

  1. Anti-dementia drug therapy (cholinesterase inhibitors or memantine) within 12 weeks prior to Screening.
  2. Clinical and/or radiological evidence for other serious degenerative neurological disorders or neuropsychiatric disorders.
  3. Known human immunodeficiency virus disease, neurosyphilis, or a history of significant head trauma followed by persistent neurological deficits or known structural brain abnormalities.
  4. Hypothyroidism at Screening.
  5. Vitamin B12 or folate deficiency at Screening.
  6. Evidence of a new transient ischemic attack (TIA) or stroke that occurs within 12 weeks prior to Screening, even if the symptoms are minor and do not require hospitalization, are excluded.
  7. Supine diastolic blood pressure ≥ 95 mmHg.
  8. Complication of sick sinus syndrome, abnormal auricular and atrioventricular (AV) junction conductions (AV block, ≥ II ventricular block, etc.), or with a prolonged QT/QTc interval (> 450 ms) as demonstrated by a repeated electrocardiogram (ECG).
  9. A history of life-threatening arrhythmias.
  10. A history of malignant neoplasms treated within 5 years prior to study entry, current evidence of malignant neoplasm, recurrent, or metastatic disease.
  11. A known or suspected history of drug or alcohol dependency or abuse.
  12. Abnormal clinical laboratory values which are judged clinically significant by the investigator.
  13. Patients who cannot swallow or who have difficulty swallowing whole tablets, as tablets should not be broken or crushed.
  14. Known plan for elective surgery that would require general anesthesia and administration of neuromuscular blocking agents.
  15. Pregnant women, lactating women, or women of child-bearing potential who don't agree to practice effective contraception throughout the entire study period and for 30 days after donepezil discontinuation, or who don't have a negative serum â-Human chorionic gonadotropin (HCG) test result or a negative urine pregnancy test result.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02660983


Locations
Layout table for location information
Korea, Republic of
Daegu-si, Buk-gu, Korea, Republic of
Seongnam-si, Bundang-gu, Korea, Republic of
Gwangju-si, Dong-gu, Korea, Republic of
Seoul-si, Dongjak-gu, Korea, Republic of
Seoul-si, Gangdong-gu, Korea, Republic of
Seoul-si, Gangnam-gu, Korea, Republic of
Chuncheon-si, Gangwon-do, Korea, Republic of
Seoul-si, Gwangjin-gu, Korea, Republic of
Anyang-si, Gyeonggi-do, Korea, Republic of
Bucheon-si, Gyeonggi-do, Korea, Republic of
Goyang-si, Gyeonggi-do, Korea, Republic of
Seongnam-si, Gyeonggi-do, Korea, Republic of
Suwon-si, Gyeonggi-do, Korea, Republic of
Wonmi-Gu, Gyeonggi-do, Korea, Republic of
Changwon-si, Gyeongsangnam-do, Korea, Republic of
Yangsan-si, Gyeongsangnam-do, Korea, Republic of
Seoul-si, Jongro-gu, Korea, Republic of
Daegu-si, Jung-gu, Korea, Republic of
Incheon-si, Jung-gu, Korea, Republic of
Seoul-si, Jungnang-Gu, Korea, Republic of
Daegu-si, Nam-gu, Korea, Republic of
Incheon-si, Namdong-gu, Korea, Republic of
Busan-si, Seo-gu, Korea, Republic of
Seoul-si, Seocho-gu, Korea, Republic of
Seoul-si, Seodaemun-Gu, Korea, Republic of
Seoul-si, Seongbuk-gu, Korea, Republic of
Seoul-si, Seongdong-gu, Korea, Republic of
Jongno-Gu, Seoul, Korea, Republic of
Seoul-si, Songpa-Gu, Korea, Republic of
Seoul-si, Yangcheon-gu, Korea, Republic of
Seoul-si, Yeongdeungpo-gu, Korea, Republic of
Sponsors and Collaborators
Eisai Co., Ltd.
  Study Documents (Full-Text)

Documents provided by Eisai Inc. ( Eisai Co., Ltd. ):
Study Protocol  [PDF] July 6, 2017
Statistical Analysis Plan  [PDF] August 17, 2015


Layout table for additonal information
Responsible Party: Eisai Co., Ltd.
ClinicalTrials.gov Identifier: NCT02660983     History of Changes
Other Study ID Numbers: E2020-K082-418
First Posted: January 21, 2016    Key Record Dates
Results First Posted: October 4, 2019
Last Update Posted: October 16, 2019
Last Verified: May 2018
Additional relevant MeSH terms:
Layout table for MeSH terms
Donepezil
Dementia
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurocognitive Disorders
Mental Disorders
Vascular Diseases
Cardiovascular Diseases
Cholinesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Cholinergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Nootropic Agents